Assessing Potential Factors Influencing the Efficacy of Immune Checkpoint Inhibitors with Radiation in Advanced Non-Small-Cell Lung Cancer Patients: A Systematic Review and Meta-Analysis
出版年份 2023 全文链接
标题
Assessing Potential Factors Influencing the Efficacy of Immune Checkpoint Inhibitors with Radiation in Advanced Non-Small-Cell Lung Cancer Patients: A Systematic Review and Meta-Analysis
作者
关键词
-
出版物
Journal of Oncology
Volume 2023, Issue -, Pages 1-17
出版商
Hindawi Limited
发表日期
2023-01-14
DOI
10.1155/2023/4477263
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Durvalumab plus tremelimumab alone or in combination with low-dose or hypofractionated radiotherapy in metastatic non-small-cell lung cancer refractory to previous PD(L)-1 therapy: an open-label, multicentre, randomised, phase 2 trial
- (2022) Jonathan D Schoenfeld et al. LANCET ONCOLOGY
- Survival Is Worse in Patients Completing Immunotherapy Prior to SBRT/SRS Compared to Those Receiving It Concurrently or After
- (2022) Susan Woody et al. Frontiers in Oncology
- First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial
- (2021) Luis Paz-Ares et al. LANCET ONCOLOGY
- Pathological response and survival with neoadjuvant therapy in melanoma: a pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC)
- (2021) Alexander M. Menzies et al. NATURE MEDICINE
- Locoregional therapies in the era of molecular and immune treatments for hepatocellular carcinoma
- (2021) Josep M. Llovet et al. Nature Reviews Gastroenterology & Hepatology
- Efficacy and Safety of Stereotactic Radiosurgery for Brainstem Metastases
- (2021) William C. Chen et al. JAMA Oncology
- 1319P Impact of bone radiotherapy on immune checkpoint inhibitors efficacy in patients with metastatic non-small cell lung cancer: A single-institution experience
- (2021) G. Nnatoli et al. ANNALS OF ONCOLOGY
- The efficacy and safety of combination therapy with immune checkpoint inhibitors in non-small cell lung cancer: A meta-analysis
- (2021) Dun-Chang Mo et al. INTERNATIONAL IMMUNOPHARMACOLOGY
- Patterns of Failure in Metastatic Non-Small Cell Lung Cancer Patients After Initiation of Pembrolizumab
- (2021) S. All et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- Clinicopathologic correlates of first-line pembrolizumab effectiveness in patients with advanced NSCLC and a PD-L1 expression of ≥ 50%
- (2020) Alessio Cortellini et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- First-line pembrolizumab in advanced non–small cell lung cancer patients with poor performance status
- (2020) Francesco Facchinetti et al. EUROPEAN JOURNAL OF CANCER
- Stereotactic ablative body radiotherapy (SABR) combined with immunotherapy (L19-IL2) versus standard of care in stage IV NSCLC patients, ImmunoSABR: a multicentre, randomised controlled open-label phase II trial
- (2020) Relinde I. Y. Lieverse et al. BMC CANCER
- SBRT combined with PD-1/PD-L1 inhibitors in NSCLC treatment: a focus on the mechanisms, advances, and future challenges
- (2020) Yu Chen et al. Journal of Hematology & Oncology
- The Effect of Advances in Lung-Cancer Treatment on Population Mortality
- (2020) Nadia Howlader et al. NEW ENGLAND JOURNAL OF MEDICINE
- LBA49 Durvalumab after chemoradiotherapy in stage III NSCLC: 4-year survival update from the phase III PACIFIC trial
- (2020) C. Faivre-Finn et al. ANNALS OF ONCOLOGY
- LBA58 ORR in patients receiving nivolumab plus radiotherapy in advanced non-small cell lung cancer: First results from the FORCE trial
- (2020) F. Bozorgmehr et al. ANNALS OF ONCOLOGY
- Atezolizumab for First-Line Treatment of PD-L1–Selected Patients with NSCLC
- (2020) Roy S. Herbst et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pembrolizumab with or without radiotherapy for metastatic non-small-cell lung cancer: a pooled analysis of two randomised trials
- (2020) Willemijn S M E Theelen et al. Lancet Respiratory Medicine
- Quantification of Scheduling Impact on Safety and Efficacy Outcomes of Brain Metastasis Radio- and Immuno-Therapies: A Systematic Review and Meta-Analysis
- (2020) Veronika Voronova et al. Frontiers in Oncology
- Immune Checkpoint Inhibitors with or without Radiotherapy in Non-Small Cell Lung Cancer Patients with Brain Metastases: A Systematic Review and Meta-Analysis
- (2020) Dong Yeong Kim et al. Diagnostics
- Radiotherapy is an independent prognostic marker of favorable prognosis in non‐small cell lung cancer patients after treatment with the immune checkpoint inhibitor, nivolumab
- (2019) Ou Yamaguchi et al. Thoracic Cancer
- Overall survival according to immunotherapy and radiation treatment for metastatic non-small-cell lung cancer: a National Cancer Database analysis
- (2019) Corey C. Foster et al. Radiation Oncology
- Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial
- (2019) Tony S K Mok et al. LANCET
- High tumor mutation burden predicts better efficacy of immunotherapy: a pooled analysis of 103078 cancer patients
- (2019) Dedong Cao et al. OncoImmunology
- Effect of Pembrolizumab After Stereotactic Body Radiotherapy vs Pembrolizumab Alone on Tumor Response in Patients With Advanced Non–Small Cell Lung Cancer
- (2019) Willemijn S. M. E. Theelen et al. JAMA Oncology
- Meta‐analysis of the difference of medians
- (2019) Sean McGrath et al. BIOMETRICAL JOURNAL
- The Effect of Radiotherapy on Clinical Outcomes for Patients Receiving Immunotherapy for Metastatic Non-Small Cell Lung Carcinoma
- (2019) K.A. D'Rummo et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- Stereotactic Radiosurgery With and Without Checkpoint Inhibition for Patients with Metastatic Non-Small Cell Lung Cancer to the Brain: A Matched Cohort Study
- (2019) Matthew Shepard et al. NEUROSURGERY
- 1517PImpact of radiotherapy on efficacy of anti-programmed death 1 (PD-1) antibodies in metastatic NSCLC
- (2019) E Samuel et al. ANNALS OF ONCOLOGY
- Prior or concurrent radiotherapy and nivolumab immunotherapy in non–small cell lung cancer
- (2019) Gishan Ratnayake et al. Asia-Pacific Journal of Clinical Oncology
- EP1.04-07 Influence of Radiotherapy in Second-Line Treatment with Immunotherapy in Patients with Non-Small Cell Lung Cancer
- (2019) E. Azkona et al. Journal of Thoracic Oncology
- Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC
- (2019) Suresh S. Ramalingam et al. NEW ENGLAND JOURNAL OF MEDICINE
- Immune Checkpoint Inhibitor Nivolumab and Radiotherapy in Pretreated Lung Cancer Patients
- (2018) Francesco Fiorica et al. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS
- Real-world Efficacy and Safety of Nivolumab for Advanced Non–Small-cell Lung Cancer: A Retrospective Multicenter Analysis
- (2018) Keigo Kobayashi et al. Clinical Lung Cancer
- The effect of thoracic radiation on overall survival and their association with systemic immune therapy in stage IV NSCLC: Findings from the National Cancer Database.
- (2018) Feng-Ming Spring Kong et al. JOURNAL OF CLINICAL ONCOLOGY
- Outcomes of immunomodulatory radiation strategies in combination with nivolumab compared with single agent nivolumab in lung cancer patients.
- (2018) Aparna Madhukeshwar Hegde et al. JOURNAL OF CLINICAL ONCOLOGY
- A retrospective analysis of the efficacy of immune checkpoint inhibitors (ICIs) to advanced non-small cell cancer (NSCLC) patients (pts) with central nerve system (CNS) metastasis.
- (2018) Takashi Sone et al. JOURNAL OF CLINICAL ONCOLOGY
- A reliable and feasible way to predict the benefits of Nivolumab in patients with non-small cell lung cancer: a pooled analysis of 14 retrospective studies
- (2018) Dedong Cao et al. OncoImmunology
- One-sample aggregate data meta-analysis of medians
- (2018) Sean McGrath et al. STATISTICS IN MEDICINE
- PUB013 Randomized Phase II Study of Pembrolizumab after SBRT versus Pembrolizumab Alone in Patients with Advanced NSCLC, Preliminary Results
- (2017) Willemijn Theelen et al. Journal of Thoracic Oncology
- Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: a secondary analysis of the KEYNOTE-001 phase 1 trial
- (2017) Narek Shaverdian et al. LANCET ONCOLOGY
- Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study
- (2016) Corey J Langer et al. LANCET ONCOLOGY
- Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement
- (2009) David Moher et al. PLOS MEDICINE
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationPublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More